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Abstract Melatonin (Ar-acetyl-5-methoxytryptamine), the prin-
cipal hormone of the vertebral pineal gland, elicits several 
neurobiological effects. However, the effects of melatonin on 
cardiac muscle are still unknown. The first goal of the study was 
to investigate the role of melatonin on myocardial contractility in 
isolated rat papillary muscle using dose-response curves to 
melatonin, to isoproterenol and calcium either in the presence or 
in the absence of melatonin (0.3 nM). Response curves to 
isoproterenol were additionally performed in the presence of 
melatonin plus the specific receptor antagonist 7V-acetyltrypta-
mine (10 uM); the adenylate-cyclase stimulator forskolin (10 
uM) was also used. 
Melatonin has no direct inotropic effect in isolated rat papillary 
muscle but counteracts isoproterenol but not [Ca2+] effects. In 
fact, the EC50 for isoproterenol was significantly higher in the 
presence than in the absence of melatonin (p < 0.001). This anti-
adrenergic action occurs through an interaction to a specific 
cardiac receptor. Forskolin-stimulated adenylate cyclase induced 
an increase of contractile force (+118 ± 25%) which was reduced 
in the presence of melatonin (+26 ± 10%; p < 0.01). 
In conclusion, we found that melatonin possess anti-adrenergic 
effect in isolated rat papillary muscle. This phenomenon was 
abolished in the presence of its receptor antagonist TV-acetyl-
tryptamine demonstrating that melatonin operates through a 
specific cardiac receptor. The reduction of contractility increase, 
induced by forskolin-stimulated adenylate cyclase, shows that 
melatonin may act through a reduction of cyclic A M P 
accumulation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Increased interest has recently gained melatonin (,/V-acetyl-
5-methoxytryptamine) since it was suggested that it is in-
volved in aging processes [1-5]. Melatonin is a circulating 
hormone that serves as an endogenous timer for mammalian 
circadian rhythms, and it may regulate the reproductive alter-
ations occurring in response to changes in day length season-
ally [6,7]. 
Melatonin exerts its action through pharmacologically spe-
cific guanine nucleotide binding protein coupled-receptors 
designated as M e h a and Mehb in various tissues including 
retina, brain, liver, spleen, and pituitary gland [8,9]. Recent 
studies of Iuvone and G a n indicate that melatonin receptors 
are coupled to inhibitory G proteins to cyclic A M P accumu-
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lation [10] and to dopamine receptor-regulated adenylate cy-
clase [11]. 
The exact action of melatonin in cardiac muscle is still un-
known. Saturable and reversible 2-l125l iodomelatonin binding 
sites has been demonstrated in heart membrane preparation 
[12]. Intravenous melatonin administration in rats produced a 
dose related-fall in mean arterial pressure and heart rate abol-
ished by pretreatment with bilateral vagotomy [13]. This latter 
study suggests that melatonin inhibits sympathetic nervous 
system. The hypothesis of an anti-adrenergic effect of melato-
nin is also supported in other experimental studies [14,15]. 
The goal of the present study was to investigate the effect of 
melatonin in isolated rat papillary muscle. We here report that 
melatonin has no direct inotropic effect on cardiac contractil-
ity. More importantly is that the dose-response curve to iso-
proterenol was shifted to the right in the presence of melato-
nin, and this phenomenon was mediated by a specific 
receptor-interaction on the heart. Our study supports the 
concept that melatonin has an anti-adrenergic action in the 
heart. 
2. Methods 
2.1. Isolated papillary muscle 
Male normotensive Wistar-Kyoto rats weighting 290 ±30 gr were 
studied (n = 22). The rats were killed by cervical dislocation, the hearts 
were quickly excised and anterior papillary muscles dissected from left 
ventricle and transferred to a tissue bath. The dissected papillary 
muscle ranged from 0.5 to 0.9 mm2 as cross-sectional area and 2-3 
mm in length, as previously described in details [16]. Muscles with 
cross-sectional area <0.5 or > 1.5 mm2 were excluded from analysis. 
The papillary muscles were superfused at 30°C with oxygenated (95% 
C0 2 , 5% 02) Tyrode solution with the following composition (mM): 
NaCl 120, KC1 5.9, MgCl2 1.2, NaHC0 3 25, NaH 2P0 4 1.2, CaCl2 I 
and glucose 11.5. The papillary muscle was tied by means of a short 
silk thread to a stainless steel rod attached to a force transducer 
(Harvard Apparatus; mod. 52-9545, 50-60 Hz). The other end of 
the strand was immobilized by means of one of the stainless steel 
pins used as stimulating electrodes. The muscle portion between the 
distal end of the muscle, connected to a force transducer and delim-
ited by L-shaped pin, could move freely during contraction. The pap-
illary muscle was continuously driven at a frequency of 60 beats/min 
(1 Hz) by means of electrical stimuli (5 msec pulses at a voltage 10% 
above threshold) delivered by a WPI stimulator (Mod. A 310 Acca-
pulser). The stimulated papillary muscles were stretched to approxi-
mately 30% of their resting length and were equilibrated for a mini-
mum of 1 hr in Tyrode solution prior to the experiments. Tension in 
response to excitation was normalized for muscle cross-sectional area 
in square millimetres (g/mm2) [16]. Resting tension (determined by 
initial muscle length), active tension (i.e. the tension developed during 
isometric contraction), and developed tension (active tension minus 
resting tension) were evaluated. 
2.2. Response to melatonin, isoproterenol and [Ca2+ ] 
Concentration response curves to melatonin were constructed in an 
incremental fashion (from 0.01 to 100 nM of final concentration). 
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Concentration response curves to isoproterenol and [Ca2+] were con-
structed in an incremental fashion in presence or absence of melatonin 
(0.3 nM). We used the 0.3 nM concentration of melatonin on the 
basis of preliminary experiments which showed similar effects in a 
range comprised between 0.1 and 1 nM. This concentration was se-
lected also because it represents the physiological nocturnal peak ob-
served in humans [17]. A maximum response both to isoproterenol 
and [Ca2+] was judged when there was no increase in contraction 
amplitude with increasing concentrations, or when toxic signs such 
a phasic contractions or decreases in diastolic length occurred. Con-
centration-response curves were used only if changes were fully rever-
sible on washout. The EC50 value (concentration for half maximal 
effect) for isoproterenol and [Ca2+] in presence or absence of melato-
nin were calculated for each papillary muscle. 
2.3. Response to N-acetyltryptamine and forskolin 
Concentration response curve to isoproterenol were constructed in 
an incremental fashion in the presence or absence of melatonin (0.3 
nM) plus the specific receptor antagonist W-acetyltryptamine (10 U.M). 
This dose was selected on the basis of our preliminary experiments 
and by previous experience in other experimental models [10], The 
EC50 value (concentration for half maximal effect) for isoproterenol 
in the presence or absence of melatonin (0.3 nM) plus the specific 
receptor antagonist was calculated for each papillary muscle. Since 
it is well known that isoproterenol induces cyclic AMP increase in 
the rat papillary muscle model [18,19], we performed experiments in 
the presence of the adenylate-cyclase stimulator forskolin (10 U.M) [10] 
in the presence and absence of 0.3 nM melatonin. 
2.4. Materials 
Melatonin (#cod. M5250), (—)-isoproterenol, and forskolin were 
obtained from Sigma Chemicals (Milan, Italy). Melatonin was solu-
bilized in ethanol (0.01%). JV-Acetyltryptamine was obtained from 
ICN Pharmaceuticals (Costa Mesa, CA; #cod. 159685). Controls 
were carried out in the presence of the same amount of ethanol 
(0.01%) used to solve melatonin. 
2.5. Data recording and statistical analysis 
Contractile force were recorded simultaneously and continuously at 
slow speed (0.05 mm/sec) with a Gould recorder (Model 2400), as 
previously described [16]. The results are reported as mean values! 
standard deviation and were analyzed with paired (-test. Isoproterenol 
curves were analyzed by the iterative non-linear least-square regres-
sion program (NFIT). The percent modification of developed tension 
in dose-response curve to melatonin was performed by considering 0% 
the contractile force at baseline while the end-scale arbitrary goes up 
to 100%). Values less than 0.05 (p<0.05) were considered significant. 
3. Results 
Our results primarily demonstrate that melatonin does not 
exert direct inotropic effect in isolated rat papillary muscle. 
Concentration response curve to melatonin shows that devel-
oped tension did not change in controls compared to muscle 
exposed to melatonin (Fig. 1, n = l). Furthermore, Table 1 
Control Melatonin 
g/mm-
0 
B 
[Melatonin], nM 
Fig. 1. Dose-response effects of melatonin (diluted in ethanol 0.01%), right) and control (ethanol 0.01%, left) on twitch tension of rat papillary 
muscle (A). (B) Superimposed twitches obtained from the experiments illustrated in A. This figure is representative of data obtained in seven 
other experiments. (C) Dose-response curve to control and melatonin on percent developed tension. Results are the mean±S.E. (« = 7). 
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Fig. 2. Dose-response effects of isoproterenol (from 0.01 to 100 nM) in the absence (Control; left) and in the presence of melatonin (0.3 nM; 
right) on twitch tension of isolated rat papillary muscle (A). (B) Superimposed twitches obtained from the experiments illustrated in A. This fig-
ure is representative of data obtained in eight other experiments. (C) Dose-response curve to isoproterenol in the absence (Control) and in the 
presence of melatonin on percent developed tension. Results are the mean ± S.E. (n = 8). 
Table 1 
Kinetics of contraction and relaxation in rat isolated papillary muscle in the different procedures at maximum dose used 
Control 
Melatonin (100 nM) 
Isoproterenol (100 nM) 
Control 
Melatonin 
[Ca2+] (4 mM) 
Control 
Melatonin 
Isoproterenol (100 nM) 
Control 
Melatonin+JV-acetyl-
tryptamine 
Forskolin (10 U.M) 
Control 
Melatonin 
Resting tension 
(g/mm2) 
2.1 ±0.5 
2.0 ±0.4 
2.4 ±0.7 
2.3 ±0.8 
2.7 ±0.6 
2.6 ±0.8 
2.4 ±0.4 
2.3 ±0.5 
2.5 ±0.5 
2.6 ±0.5 
Developed tension 
(g/mm2) 
3.4 ±0.4 
3.3 ±0.6 
6.1 ±0.7 
5.9 ±0.8 
7.3 ±0.9 
7.2 ±1.0 
6.2 ±0.8 
6.0 ±0.7 
7.4±1.0 
4.1 ±0.5* 
Time to peak 
(ms) 
113 ± 15 
115 + 18 
87 ±8 
114±6* 
108 ±11 
111 + 12 
85±6 
84±9 
93 ±5 
112±4* 
Half contraction 
time (ms) 
65 ±7 
68 ±5 
52±5 
63 ±5* 
62±6 
65±4 
54±3 
51 ±4 
50±5 
66 ± 3 * 
Half relaxation 
time (ms) 
105 ±9 
110±8 
81±6 
101 ±7* 
101 ±5 
106 ±4 
103 ±6 
109 ±4 
84±9 
108 ±4* 
Results are expressed as mean ± S.E. 
*p < 0.05 vs. respective Control. 
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Fig. 3. Dose-response effects of [Ca2+]o (from 0 to 4 mM) in the absence (Control; left) and in the presence of melatonin (0.3 nM; right) on 
twitch tension of papillary rat muscle (A). (B) Superimposed twitches obtained from the experiments illustrated in A. This figure is representa-
tive of data obtained in seven other experiments. (C) Dose-response curve to [Ca2+]o in the absence (Control) and in the presence of melatonin 
on percent developed tension. Results are the mean ± S.E. (n = 1). 
indicates that melatonin, at the highest dose used, did not 
show difference on kinetics of contraction and relaxation com-
pared to control. 
The |3-adrenoreceptor agonist isoproterenol effects in the 
presence or in the absence of melatonin are shown in Fig. 2 
(n = 8). Concentration response curve to isoproterenol on de-
veloped tension in controls shows a physiological trend begin-
ning to increase at 0.1 nM. In contrast, in the presence of 
melatonin the curve was significantly shifted to the right be-
ginning to increase at 3 nM. In addition, isoproterenol in-
duced a reduction of time to peak, half contraction and relax-
ation time (Table 1); these modifications were significantly 
reduced in the presence of melatonin. Table 2 shows that 
isoproterenol concentration required to obtain 50% of devel-
oped tension (EC50) was significantly higher in the presence of 
melatonin (p < 0.001). 
In order to investigate whether melatonin effect on contrac-
tile response to isoproterenol was mediated by a direct action 
on calcium-dependent contractile mechanism, [Ca2+] concen-
tration curves were performed. Fig. 3 depicts that increasing 
developed tension to [Ca2+] was similar between controls ansd 
melatonin-treated papillary muscles (« = 7). No difference was 
estimated in EC50 for calcium concentration curves both in 
the presence or absence of melatonin (p - N.S.; Table 2) in-
dicating that melatonin action on contractile response was 
mediated by a calcium-independent mechanism. 
Therefore, in order to investigate whether melatonin acts 
through a specific receptor interaction, we tested the effects 
of the specific melatonin receptor antagonist ./V-acetyltrypt-
amine. The antagonist prevented melatonin from shifting 
the EC50 and kinetic contraction modifications induced by 
isoproterenol and (Fig. 4, Tables 1 and 2). 
Table 2 
EC50 for isoproterenol in controls, and in the presence of melatonin 
alone, or plus the specific receptor antagonist Af-acetyltryptamine 
(10 uM), and for [Ca2+] in controls, and in the presence of melato-
nin 
Control 
Melatonin 
Melatonin+JV-
tryptamine 
acetyl-
Isoproterenol (nM) 
1.16±0.12 
12.98 ±1.68* 
1.19±0.14 
[Ca2+] (mM) 
1.63±0.19 
1.52±0.16 
Results are the mean ± S.E. of different experiments (see Section 3). 
*p < 0.001 vs. Control. 
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Control 
Melatonin 
+ 
N-Acetyltryptamine 
B 0.01 0.1 1 10 100 nM B 0.01 0.1 1 10 100 nM 
g/mm2 
B 
g/mm2 g/mm
2 
200 ms 200 ms 
100 
80 
S 60 
Melatonin 
+ 
N-Acetyltryptamine 
Control 
Melatonin + N-Acetyltryptamine 
I M i l l ) 
100 1000 
Log [Isoproterenol], nM 
Fig. 4. Dose-response effects of isoproterenol (from 0.01 to 100 nM) in the absence (Control; left) and in the presence of melatonin (0.3 nM; 
right) plus its specific receptor antagonist iV-acetyltryptamine (10 uM) on twitch tension of papillary rat muscle (A). (B) Superimposed twitches 
obtained from the experiments illustrated in A. This figure is representative of data obtained in eight other experiments. (C) Dose-response 
curve to isoproterenol in the absence (Control) and in the presence of melatonin plus its specific receptor antagonist JV-acetyltryptamine on per-
cent developed tension. Results are the mean ± S.E. (n = 7). 
The mechanism of this receptor-interaction mecha-
nism was also investigated by the stimulation of adenylate 
cyclase, and therefore c A M P accumulation, by forskolin. 
This set of experiments showed that forskolin increased the 
force of contraction in a similar fashion as isoproterenol 
(+118 ±25%) . This phenomenon was significantly reduced 
in the presence of melatonin (+26 ± 1 0 % ; /J < 0.01) (Fig. 5, 
Table 1). 
4. Discussion 
Our results demonstrate that melatonin has no direct ino-
tropic effect in isolated rat papillary muscle. More impor-
tantly is that melatonin counteracts isoproterenol but not 
[Ca2 +] effect. The anti-adrenergic action of melatonin in car-
diac muscle occurs through an interaction to a specific cardiac 
receptor. The relative reduction of contractility increase, in-
duced by forskolin-stimulated adenylate cyclase, shows that 
melatonin may act through a reduction of c A M P accumula-
tion. The results of the present study confirm the anti-adre-
nergic action of melatonin found in other tissues [8-11]. 
Melatonin participates in several physiological functions, 
such as the control of seasonal reproduction as well as the 
immune system [6,7]. Experimental evidence suggests that 
melatonin acts by suppressing peripheral sympathetic activity 
and reducing noradrenaline turnover in the heart [20]. In ad-
dition, melatonin reduces norepinephrine and epinephrine 
content in adrenal gland [21]. Administration of melatonin 
in vivo determined a reduction of heart rate in baboon [22] 
and both arterial pressure and heart rate in rats [13] as the 
result of a hypothetical sympathetic inhibition. In fact, mela-
tonin has been proposed as endogenous hypotensive factor 
probably by stimulating central inhibitory adrenergic path-
ways [23]. Our results firstly demonstrate that melatonin ex-
erts a specific sympathetic antagonism in rat isolated papillary 
muscle which is an experimental model where central nervous 
system control and other hormonal influences are excluded. 
Melatonin has two specific receptors (Meli a and Meln,) 
84 P. Abete et al.lFEBS Letters 412 (1997) 79-85 
Forskolin 
Melatonin 
+ 
Forskolin 
B B Forskolin 10 |iM B M Forskolin 10 uM 
0.3 nM 
g/mm2 
B 
Forskolin Melatonin 
Forskolin 
Fig. 5. Effects of 10 uM forskolin in the absence (forskolin; left) and in the presence of melatonin (0.3 nM; right) on twitch tension of papil-
lary rat muscle (A). (B) Superimposed twitches obtained from the experiments illustrated in A. This figure is representative of data obtained in 
eight other experiments. (C) Effects of forskolin in the absence and in the presence of melatonin on percent developed tension. Results are the 
mean±S.E. (n = 8). 
linked to G-protein system in various tissues such as retina, 
brain, liver, spleen, and pituitary gland [8,9]. These receptors 
are coupled to inhibition of adenyl-cyclase, and, therefore, 
may negatively modulate the adrenergic system [8,9]. Further-
more, melatonin receptors are coupled to inhibitory G pro-
teins to cyclic AMP accumulation [10] and to dopamine re-
ceptor-regulated adenylate cyclase [11]. The presence of a 
melatonin cardiac receptor is not well established. In a recent 
report, specific 2-'125l iodomelatonin binding sites were dem-
onstrated in heart membrane preparations [12]. In order to 
examine the mechanism of action of melatonin at the level 
of receptor coupling on isoproterenol response, we used the 
specific receptor antagonist TV-acetyltryptamine [24]. We 
found that melatonin effects on isoproterenol response was 
abolished in the presence of its receptor antagonist. This dem-
onstrates that melatonin operates through a specific cardiac 
receptor demonstrating the presence of melatonin receptor in 
cardiac muscle similarly to other tissues [8,9]. A more prob-
able explanation for the mechanism of receptor-interaction is 
the coupling of a melatonin receptor in papillary muscle to 
adenylate cyclase via an inhibitory G; protein. In this scenar-
io, melatonin, by activating Gi protein, would prevent the 
activation of adenylate cyclase by isoproterenol, and prevent 
a subsequent rise in cyclic AMP by isoproterenol, as previ-
ously showed [18,19]. This mechanism, in turn, would lower 
the efficacy of isoproterenol in inducing contraction in cardiac 
tissue. To test this hypothesis, we investigated whether the 
adenylate cyclase stimulator forskolin [25] increases the force 
of contraction in a similar fashion as isoproterenol, and 
successively, we tested the action of melatonin in this mecha-
nism. We demonstrated that this hypothesis was correct. 
In fact, forskolin increased the force of contraction in a sim-
ilar fashion as isoproterenol while melatonin reduced its 
action. 
In conclusion, we found that melatonin possess anti-adre-
nergic effect in cardiac tissue. This was abolished in the pres-
ence of its receptor antagonist iV-acetyltryptamine demon-
strating that melatonin acts through a specific cardiac 
receptor. The reduction of contractility increase, induced by 
forskolin-stimulated adenylate cyclase, shows that melatonin 
P. Abete et al.lFEBS Letters 412 (1997) 79-85 
may exert its action through a reduction of cyclic A M P accu-
mulation. 
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